Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 90Prostatic Neoplasms 55Lymphoma 34Leukemia 32Carcinoma, Non-Small-Cell Lung 31Multiple Myeloma 30Head and Neck Neoplasms 30Colorectal Neoplasms 29Squamous Cell Carcinoma of Head and Neck 28Lung Neoplasms 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Colonic Neoplasms 24Leukemia, Myeloid, Acute 22Rectal Neoplasms 21Neoplasm Metastasis 20Sarcoma 19Ovarian Neoplasms 19Central Nervous System Neoplasms 18Uterine Cervical Neoplasms 17Hodgkin Disease 17Burkitt Lymphoma 15Brain Neoplasms 15Carcinoma, Ovarian Epithelial 14Pain 12Lymphoma, Follicular 12Urinary Bladder Neoplasms 11Lymphoma, Large B-Cell, Diffuse 11Fallopian Tube Neoplasms 11Endometrial Neoplasms 11Astrocytoma 11

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × NETWORK × Recurrent Uterine Corpus Carcinoma × Clear all
NCT00063999 2021-10-19

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

GOG Foundation

Phase 3 Completed
1,381 enrolled 12 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡